Iron Deficiency Anaemia Clinical Trial
Official title:
A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.
Verified date | November 2013 |
Source | Medical Research Council |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Councils UK |
Study type | Interventional |
Iron deficiency is the most common micronutrient deficiency in the world today, affecting more than 60% of the global population (www.who.int/nut/ida.htm). The two main strategies for the prevention and treatment of iron deficiency involve fortification of food with iron, or direct supplementation with iron tablets. Simple iron salts (e.g. ferrous sulphate) are well absorbed but at supplemental levels (and potentially at lower levels, as used in food fortificants) can induce free radical activity resulting in gastrointestinal side effects and systematic oxidative stress. As a result, supplementation has poor compliance and improvement in iron status is compromised. Ferric salts are less inclined to produce side effects and although they are relatively well absorbed at fortification levels in food, they are poorly absorbed at the higher supplemental doses. Because certain components of food, such as organic acids, can facilitate ferric iron absorption, we now wish to determine whether dietary organic acids may similarly enable efficient absorption of supplemental ferric iron while preventing the formation of non-transferrin-bound iron (NTBI) which is a proxy for free radical activity. Our strategy is to use an iterative process between in vitro and in vivo experimentation, aimed at identifying the best choice of organic acid and the optimal ratio of iron:organic acid. The study was a cross-over, single-dose comparison against standard-of-care therapy (namely ferrous sulphate) in mildly iron deficient anaemic women. Both the investigational products and the active comparator were administered as a single dose on 2 different occasions, i.e. the investigational products on the first study visit and the active comparator 14 days later on the second study visit.
Status | Completed |
Enrollment | 71 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Female aged 18-45 years. Low iron stores based on one of the following criteria: (I) Mild iron deficiency anaemia defined as haemoglobin between 10-11.9 g/dL plus either a serum ferritin less than 20 µg/L or transferrin saturation < 10% or (II) iron deficiency defined as a serum ferritin less than 12 µg/L. Exclusion Criteria: - pregnancy and lactation - surgery in the past three months - cancer in last ten years - known chronic infection - chronic inflammation - moderate or severe anaemia - known cardiovascular disease - chronic respiratory disease. - history of hereditary haemochromatosis or haemoglobinopathies - current proton pump inhibitor medication - blood donation/heavy blood loss in the last 3 months - iron supplementation in the past 1 month - chronic liver disease - renal disease - Coeliac Disease |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United Kingdom | MRC Human Nutrition Research | Cambridge | Cambridgeshire |
Lead Sponsor | Collaborator |
---|---|
Medical Research Council |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Iron Bioavailability | The primary outcome was bioavailability of iron from ferric iron oxide-organic acid preparations (Fe-OA) as measured by erythrocyte incorporation of labelled iron (58Fe). | 14 days | No |
Secondary | Iron absorption | The secondary outcomes were total iron absorption and the rates of iron absorption in the 4 hours following the ingestion of the ferric iron oxide-organic acid preparations (Fe-OA)and the active comparator (namely ferrous sulphate). | 4 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03237065 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT03238911 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT02940886 -
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
|
Phase 3 | |
Completed |
NCT02940860 -
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02965209 -
European Novel Motorized Spiral Endoscopy Trial
|
N/A | |
Completed |
NCT02130063 -
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
|
Phase 3 | |
Completed |
NCT01878734 -
Zambia Micronutrient Powder Trial Effectiveness Study
|
N/A | |
Completed |
NCT02962648 -
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
|
Phase 3 | |
Completed |
NCT02546154 -
Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)
|
||
Completed |
NCT00994318 -
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
|
Phase 3 | |
Completed |
NCT01340872 -
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
|
Phase 3 | |
Completed |
NCT01352221 -
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
|
Phase 3 | |
Recruiting |
NCT05990166 -
Assessing the Effect of a Mineral-enriched Powder on Iron Deficiency in Women of Reproductive Age
|
Phase 2 | |
Not yet recruiting |
NCT06276140 -
Iron-deficiency Anaemia and Its Impact on Recovery After Colorectal Cancer Surgery
|